1 / 27

Nicola Cooper

Estimating the cost-effectiveness of an intervention in a clinical trial when partial cost information is available: A Bayesian approach. Nicola Cooper Centre for Biostatics and Genetic Epidemiology, Department of Health Science,University of Leicester, UK. Co-authors:

riley-bruce
Download Presentation

Nicola Cooper

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Estimating the cost-effectiveness of an intervention in a clinical trial when partial cost information is available: A Bayesian approach Nicola Cooper Centre for Biostatics and Genetic Epidemiology, Department of Health Science,University of Leicester, UK Co-authors: Paul Lambert, Alex Sutton, Keith Abrams (Centre for Biostatics and Genetic Epidemiology, Department of Health Science,University of Leicester, UK), Cindy Billingham (Cancer Research UK Trials Unit, University of Birmingham, UK) Econometric Methods for Correcting for Missing Cost & Utilization Data 5th World iHEA Congress, Barcelona, July 2005

  2. OBJECTIVE • Assess cost-effectiveness when partial or no cost data is available for some individuals randomised into a trial • Develop a Bayesian model to address: • Complexities of missing cost component data • Interrelationships between cost and survival • Semi-continuous distribution of cost data (proportion have zero cost)

  3. BACKGROUND TO THE MIC2 TRIALCullen MH, Billingham LJ et al (1999) J ClinOncol ; 17: 3188-3194 Extensive stage non-small cell lung cancer Randomise 11/88 - 03/96: 351 eligible patients PAL Standard palliative care CT+PAL Chemotherapy + palliative care Primary endpoint: survival, Secondary endpoints: response, toxicity, QoL Results: CT+PAL gave a median additional 2 months extra survival time (p=0.03)

  4. MIC2 COSTINGS STUDYBillingham LJ, et al. Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2002; 37: 219-225. • Retrospective study initiated in 1995 • Subgroup of 116 West Midlands patients • Aim: examine patterns of care and costs on both treatment arms • Timeframe: trial entry to death • Perspective: health service • Details of care obtained from hospital, GP and hospice notes • Full details obtained for 82 patients Note: Treatment cost component available for most trial patients

  5. MISSING DATA PROBLEM • Retrospective design  missing patient notes 34 patients have at least one cost component missing and hence total cost missing Survival time data available for all 351 patients in trial All patients, except 7, dead at time of analysis

  6. COST DATA DESCRIPTION

  7. MODELLING DETAILS • All models estimated using Markov chain Monte Carlo methods using WinBUGS • All prior distributions intended to be vague

  8. MODEL 1: Complete case • Re-parameterisation of O’Hagan et al.(2001): Assumes survival and cost have a bivariate Normal distribution where Sgidenotes the survival time for the ith individual in the gth treatment group & Cgi the corresponding total cost. • Applied to only patients with complete cost & effectiveness data

  9. MODEL 1(cont.) • Difference in mean survival time & cost between treatment groups calculated & incremental net monetary benefit statistic calculated for different values of  • A plot of the sampled values of the survival & cost difference produces the cost-effectiveness plane • An acceptability curve can also be constructed

  10. Cost: n = 82, Clinical: n = 82 NE - CT more effective, but more costly SE - CT more effective and less costly SW - PAL more effective, but more costly NW - PAL more effective and less costly

  11. MODEL 2:Modelling missing cost components assuming multivariate normality • Total cost split into 4 component costs: Treatment (TRT), GP, Hospital (HL), Hospice (HL). • Models the joint distribution of the 4 cost components and survival • Expressed as 5 interrelated conditional univariate distributions • Applied to all patients in the economic sub-study

  12. Cost Components GP Treatment Hospital Hospice Survival Time Survival Time Total Cost Total Cost Cost Difference Survival Difference CT Group PAL Group Net Monetary Benefit

  13. MODEL 2(cont.) • The interrelationship between each cost component & survival is allowed to vary between the two treatment groups, as is the variance of the cost components • The interrelationship between the cost components is the same in both treatment groups • All variables centred at their mean; thus 11, 11, 11, & 11 are the mean costs for treatment, GP, hospital and hospice respectively

  14. MODEL 2(cont.) • The mean total cost for an individual in each treatment group is then calculated • As before, the difference between groups for survival time and cost is then calculated and a cost-effectiveness plane, etc. constructed

  15. Cost: n = 115, Clinical: n = 115 Cost: n = 82, Clinical: n = 82

  16. MODEL 3: Incorporation of semi-continuous distribution for one of the cost components • As Model 2 but a hurdle (delta or two-part) model is applied to the Hospice cost component (Cooper et al. MDM 2003) • Considerable proportion (63%) of patients had zero cost for hospice (i.e. they did not go to one) • Models the probability the hospice cost is zero using logistic regression • Then fits a linear regression model to the positive values • Predicted cost for an individual is given by the expected cost (obtained from linear model) multiplied by probability of incurring a cost (obtained from logistic model)

  17. MODEL 3: DISTRIBUTION OF HOSPICE COST

  18. MODEL 3: DATASETS • Model 3a: all patients in the economic sub-study (n=115) • Model 3b:all patients in the economic sub-study for costs (n=115) and all trial patients for effectiveness (n=351) • Model 3c: All trial participants to estimate both cost (n=351) and effect (n=351)

  19. Cost: n = 115, Clinical: n = 115 Cost: n = 115, Clinical: n = 115 Cost: n = 82, Clinical: n = 82 Model 3a Model 3b Model 3c

  20. Cost: n = 115, Clinical: n = 115 Cost: n = 115, Clinical: n = 115 Cost: n = 82, Clinical: n = 82 Model 3a Cost: n = 115, Clinical: n = 351 Model 3c Model 3b

  21. Cost: n = 115, Clinical: n = 115 Cost: n = 115, Clinical: n = 115 Cost: n = 82, Clinical: n = 82 Model 3a Cost: n = 115, Clinical: n = 351 Cost: n = 351, Clinical: n = 351 Model 3c Model 3b

  22. ACCEPTABILITY CURVES FOR MODELS Model 1 Model 2 Model 3a Model 3b Model 3c £2000

  23. CONCLUSIONS • Design & analysis of cost studies is important • Maximise information use taking into account parameter uncertainty • MCMC very flexible for these complex models • Much simpler if no missing data! (But often unrealistic)

  24. FURTHER ISSUES • Other distributions/transformations for cost data • Breaking down cost components to item use? • Too many parameters? • Take account of censoring • Adding other covariates • Incorporate Quality of Life (in this example measured on a different sub-sample) Copy of slides available at: http://www.hs.le.ac.uk/personal/njc21/

More Related